vs
Side-by-side financial comparison of Ovintiv Inc. (OVV) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
Ovintiv Inc. is the larger business by last-quarter revenue ($2.1B vs $1.1B, roughly 1.9× PERRIGO Co plc). Ovintiv Inc. runs the higher net margin — 46.1% vs -127.8%, a 173.9% gap on every dollar of revenue. On growth, PERRIGO Co plc posted the faster year-over-year revenue change (-2.5% vs -6.0%). Ovintiv Inc. produced more free cash flow last quarter ($489.0M vs $148.6M). Over the past eight quarters, PERRIGO Co plc's revenue compounded faster (1.3% CAGR vs -7.2%).
Ovintiv Inc. is a U.S. petroleum company based in Denver. The company was formed in 2020 through a restructuring of its Canadian predecessor, Encana.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
OVV vs PRGO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.1B | $1.1B |
| Net Profit | $946.0M | $-1.4B |
| Gross Margin | — | 32.6% |
| Operating Margin | 21.2% | -116.0% |
| Net Margin | 46.1% | -127.8% |
| Revenue YoY | -6.0% | -2.5% |
| Net Profit YoY | 1676.7% | -3093.9% |
| EPS (diluted) | $3.64 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.1B | $1.1B | ||
| Q3 25 | $2.0B | $1.0B | ||
| Q2 25 | $2.2B | $1.1B | ||
| Q1 25 | $2.4B | $1.0B | ||
| Q4 24 | $2.2B | $1.1B | ||
| Q3 24 | $2.2B | $1.1B | ||
| Q2 24 | $2.2B | $1.1B | ||
| Q1 24 | $2.4B | $1.1B |
| Q4 25 | $946.0M | $-1.4B | ||
| Q3 25 | $148.0M | $7.5M | ||
| Q2 25 | $307.0M | $-8.4M | ||
| Q1 25 | $-159.0M | $-6.4M | ||
| Q4 24 | $-60.0M | $-44.4M | ||
| Q3 24 | $507.0M | $-21.0M | ||
| Q2 24 | $340.0M | $-108.4M | ||
| Q1 24 | $338.0M | $2.0M |
| Q4 25 | — | 32.6% | ||
| Q3 25 | — | 36.1% | ||
| Q2 25 | — | 34.4% | ||
| Q1 25 | — | 37.6% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | — | 37.2% | ||
| Q2 24 | — | 37.0% | ||
| Q1 24 | — | 33.1% |
| Q4 25 | 21.2% | -116.0% | ||
| Q3 25 | 13.5% | 7.0% | ||
| Q2 25 | 23.1% | 4.3% | ||
| Q1 25 | -3.7% | 4.5% | ||
| Q4 24 | 0.1% | 10.0% | ||
| Q3 24 | 24.2% | 7.4% | ||
| Q2 24 | 25.4% | -2.5% | ||
| Q1 24 | 20.7% | -5.1% |
| Q4 25 | 46.1% | -127.8% | ||
| Q3 25 | 7.3% | 0.7% | ||
| Q2 25 | 13.9% | -0.8% | ||
| Q1 25 | -6.7% | -0.6% | ||
| Q4 24 | -2.7% | -3.9% | ||
| Q3 24 | 23.3% | -1.9% | ||
| Q2 24 | 15.5% | -10.2% | ||
| Q1 24 | 14.2% | 0.2% |
| Q4 25 | $3.64 | $-10.23 | ||
| Q3 25 | $0.57 | $0.05 | ||
| Q2 25 | $1.18 | $-0.06 | ||
| Q1 25 | $-0.61 | $-0.05 | ||
| Q4 24 | $-0.22 | $-0.32 | ||
| Q3 24 | $1.92 | $-0.15 | ||
| Q2 24 | $1.27 | $-0.79 | ||
| Q1 24 | $1.24 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $280.0M | — |
| Total DebtLower is stronger | $5.2B | — |
| Stockholders' EquityBook value | $11.2B | $2.9B |
| Total Assets | $20.4B | $8.5B |
| Debt / EquityLower = less leverage | 0.46× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $280.0M | — | ||
| Q3 25 | $25.0M | $432.1M | ||
| Q2 25 | $20.0M | $454.2M | ||
| Q1 25 | $8.0M | $409.9M | ||
| Q4 24 | $42.0M | $558.8M | ||
| Q3 24 | $9.0M | $1.5B | ||
| Q2 24 | $8.0M | $542.8M | ||
| Q1 24 | $5.0M | $658.5M |
| Q4 25 | $5.2B | — | ||
| Q3 25 | $5.2B | — | ||
| Q2 25 | $5.3B | — | ||
| Q1 25 | $5.5B | — | ||
| Q4 24 | $5.5B | — | ||
| Q3 24 | $5.9B | — | ||
| Q2 24 | $6.1B | — | ||
| Q1 24 | $6.2B | — |
| Q4 25 | $11.2B | $2.9B | ||
| Q3 25 | $10.2B | $4.4B | ||
| Q2 25 | $10.4B | $4.5B | ||
| Q1 25 | $10.1B | $4.4B | ||
| Q4 24 | $10.3B | $4.3B | ||
| Q3 24 | $10.7B | $4.6B | ||
| Q2 24 | $10.3B | $4.5B | ||
| Q1 24 | $10.3B | $4.7B |
| Q4 25 | $20.4B | $8.5B | ||
| Q3 25 | $19.4B | $10.1B | ||
| Q2 25 | $19.7B | $10.1B | ||
| Q1 25 | $19.6B | $9.8B | ||
| Q4 24 | $19.3B | $9.6B | ||
| Q3 24 | $19.9B | $11.2B | ||
| Q2 24 | $19.8B | $10.4B | ||
| Q1 24 | $19.8B | $10.6B |
| Q4 25 | 0.46× | — | ||
| Q3 25 | 0.51× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.55× | — | ||
| Q2 24 | 0.59× | — | ||
| Q1 24 | 0.60× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $954.0M | $175.4M |
| Free Cash FlowOCF − Capex | $489.0M | $148.6M |
| FCF MarginFCF / Revenue | 23.8% | 13.4% |
| Capex IntensityCapex / Revenue | 22.6% | 2.4% |
| Cash ConversionOCF / Net Profit | 1.01× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.5B | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $954.0M | $175.4M | ||
| Q3 25 | $812.0M | $51.7M | ||
| Q2 25 | $1.0B | $75.9M | ||
| Q1 25 | $873.0M | $-64.5M | ||
| Q4 24 | $1.0B | $312.6M | ||
| Q3 24 | $1.0B | $42.2M | ||
| Q2 24 | $1.0B | $9.5M | ||
| Q1 24 | $659.0M | $-1.4M |
| Q4 25 | $489.0M | $148.6M | ||
| Q3 25 | $268.0M | $29.8M | ||
| Q2 25 | $492.0M | $56.7M | ||
| Q1 25 | $256.0M | $-90.0M | ||
| Q4 24 | $468.0M | $274.9M | ||
| Q3 24 | $484.0M | $15.1M | ||
| Q2 24 | $398.0M | $-18.9M | ||
| Q1 24 | $68.0M | $-26.5M |
| Q4 25 | 23.8% | 13.4% | ||
| Q3 25 | 13.3% | 2.9% | ||
| Q2 25 | 22.2% | 5.4% | ||
| Q1 25 | 10.8% | -8.6% | ||
| Q4 24 | 21.4% | 24.2% | ||
| Q3 24 | 22.2% | 1.4% | ||
| Q2 24 | 18.1% | -1.8% | ||
| Q1 24 | 2.8% | -2.4% |
| Q4 25 | 22.6% | 2.4% | ||
| Q3 25 | 26.9% | 2.1% | ||
| Q2 25 | 23.5% | 1.8% | ||
| Q1 25 | 26.0% | 2.4% | ||
| Q4 24 | 25.3% | 3.3% | ||
| Q3 24 | 24.7% | 2.5% | ||
| Q2 24 | 28.4% | 2.7% | ||
| Q1 24 | 24.8% | 2.3% |
| Q4 25 | 1.01× | — | ||
| Q3 25 | 5.49× | 6.89× | ||
| Q2 25 | 3.30× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.02× | — | ||
| Q2 24 | 3.00× | — | ||
| Q1 24 | 1.95× | -0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OVV
| Product And Service Revenue | $1.7B | 84% |
| Sales Of Purchased Product | $338.0M | 16% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
